DUNDEE, United Kingdom--(BUSINESS WIRE)--ex scientia Ltd., the polypharmacology driven drug discovery company, announced today that they have signed an agreement with Sunovion Pharmaceuticals Inc., to collaborate on the discovery and optimisation of novel medicines for psychiatric disorders. As part of the new strategic alliance, worth $4.8 million (USD), ex scientia received an upfront payment of $1 million (USD). Under the terms of the agreement, Sunovion will receive exclusive worldwide rights to the resulting compounds whereas ex scientia retains exclusive rights to its technology.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
